U.S. flag

An official website of the United States government

NM_000330.4(RS1):c.375_378del (p.Ile125_Asp126insTer) AND not provided

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
Mar 7, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000085288.11

Allele description [Variation Report for NM_000330.4(RS1):c.375_378del (p.Ile125_Asp126insTer)]

NM_000330.4(RS1):c.375_378del (p.Ile125_Asp126insTer)

Genes:
CDKL5:cyclin dependent kinase like 5 [Gene - OMIM - HGNC]
RS1:retinoschisin 1 [Gene - OMIM - HGNC]
Variant type:
Microsatellite
Cytogenetic location:
Xp22.13
Genomic location:
Preferred name:
NM_000330.4(RS1):c.375_378del (p.Ile125_Asp126insTer)
HGVS:
  • NC_000023.11:g.18644574ATCT[1]
  • NG_008475.1:g.223970ATCT[1]
  • NG_008659.3:g.37868AGAT[1]
  • NM_000330.4:c.375_378delMANE SELECT
  • NM_001037343.2:c.2714-1429_2714-1426del
  • NM_003159.3:c.2714-1429_2714-1426del
  • NP_000321.1:p.Asp126Terfs
  • NP_000321.1:p.Ile125_Asp126insTer
  • LRG_702t1:c.371_374AGAT[1]
  • LRG_702:g.37868AGAT[1]
  • LRG_702p1:p.Asp126Terfs
  • NC_000023.10:g.18662694ATCT[1]
  • NM_000330.3:c.371_374AGAT[1]
  • NM_000330.3:c.375_378delAGAT
Links:
dbSNP: rs61752148
NCBI 1000 Genomes Browser:
rs61752148
Molecular consequence:
  • NM_000330.4:c.375_378del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001037343.2:c.2714-1429_2714-1426del - intron variant - [Sequence Ontology: SO:0001627]
  • NM_003159.3:c.2714-1429_2714-1426del - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000117425Retina International
no classification provided
not providedunknownnot provided

SCV000565499GeneDx
criteria provided, single submitter

(GeneDx Variant Classification (06012015))
Pathogenic
(Mar 7, 2017)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providednot providednot providednot providednot providednot provided1not providedliterature only

Details of each submission

From Retina International, SCV000117425.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providednot providednot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownnot provided1not providednot providednot providednot providednot providednot provided

From GeneDx, SCV000565499.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The c.375_378delAGAT pathogenic variant in the RS1 gene has been reported previously in association with X-linked juvenile retinoschisis (Retinoschisis Consortium 1998; Hiriyanna et al., 1999; Tantri et al., 2003). It changes codon Aspartic acid 126 to a premature Stop codon, denoted p.Asp126Ter. This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024